May 21, 2021 - Contract Pharma
Premier Research is a provider of strategic and regulatory advisory services as well as clinical development services to the biotechnology, specialty pharma, and medical device industry. Camargo is a global strategy, regulatory, and commercial partner for emerging biopharma companies and has experience in complex development programs and accelerated approval pathways that leverages their expertise in areas such as oncology, pediatrics, rare disease, and 505(b)(2) product development.
May 20, 2021 - Contract Pharma
This new agreement is in addition to the 600 million doses already committed to the EU through 2021. The additional 900 million agreed doses are expected to be delivered on a monthly schedule beginning December 2021 and continuing into 2023. As part of the agreement, the EC also has an option to increase the number of doses delivered by up to an additional 900 million, bringing the total number of potential doses delivered to the EC, inclusive of all agreements, to up to 2.4 billion. All doses for the EC are planned to be manufactured in the EU.
May 20, 2021 - Fierce Pharma
As GSK forges ahead with its plan to split into two by next year, the pharma giant has unveiled plans to sell its entire stake in respiratory drug partner Innoviva for roughly $392 million.
May 19, 2021 - Fierce Biotech
Where there’s smoke there’s fire, and hot on the heels of closing more than a half-billion dollars in venture capital funding, Exscientia announced a drug discovery deal with Bristol Myers Squibb that could pay out up to $1.2 billion or more.
